Journal article 441 views 543 downloads
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Deborah B Horn,
Donna H Ryan,
Sanja Giljanovic Kis,
Breno Alves,
Yiming Mu,
Sin Gon Kim,
Jens Aberle,
Steve Bain 
,
Sheryl Allen,
Elizabeth Sarker,
Qiwei Wu,
Adam Stefanski,
Irina Jouravskaya
,
Sheryl Allen,
Elizabeth Sarker,
Qiwei Wu,
Adam Stefanski,
Irina Jouravskaya
The Lancet, Volume: 406, Issue: 10522, Pages: 2927 - 2944
Swansea University Author:
Steve Bain
-
PDF | Accepted Manuscript
Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention).
Download (232.99KB)
DOI (Published version): 10.1016/s0140-6736(25)02165-8
Abstract
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
| Published in: | The Lancet |
|---|---|
| ISSN: | 0140-6736 1474-547X |
| Published: |
Elsevier BV
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa71022 |
| first_indexed |
2025-11-28T13:41:45Z |
|---|---|
| last_indexed |
2026-02-24T05:32:28Z |
| id |
cronfa71022 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2026-02-23T14:49:51.5366031</datestamp><bib-version>v2</bib-version><id>71022</id><entry>2025-11-28</entry><title>Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-11-28</date><deptcode>MEDS</deptcode><abstract/><type>Journal Article</type><journal>The Lancet</journal><volume>406</volume><journalNumber>10522</journalNumber><paginationStart>2927</paginationStart><paginationEnd>2944</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0140-6736</issnPrint><issnElectronic>1474-547X</issnElectronic><keywords/><publishedDay>20</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-12-20</publishedDate><doi>10.1016/s0140-6736(25)02165-8</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Not Required</apcterm><funders>This study was funded by Eli Lilly and Company.</funders><projectreference/><lastEdited>2026-02-23T14:49:51.5366031</lastEdited><Created>2025-11-28T13:40:28.3195636</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Deborah B</firstname><surname>Horn</surname><order>1</order></author><author><firstname>Donna H</firstname><surname>Ryan</surname><order>2</order></author><author><firstname>Sanja Giljanovic</firstname><surname>Kis</surname><order>3</order></author><author><firstname>Breno</firstname><surname>Alves</surname><order>4</order></author><author><firstname>Yiming</firstname><surname>Mu</surname><order>5</order></author><author><firstname>Sin Gon</firstname><surname>Kim</surname><order>6</order></author><author><firstname>Jens</firstname><surname>Aberle</surname><order>7</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>8</order></author><author><firstname>Sheryl</firstname><surname>Allen</surname><order>9</order></author><author><firstname>Elizabeth</firstname><surname>Sarker</surname><order>10</order></author><author><firstname>Qiwei</firstname><surname>Wu</surname><order>11</order></author><author><firstname>Adam</firstname><surname>Stefanski</surname><order>12</order></author><author><firstname>Irina</firstname><surname>Jouravskaya</surname><order>13</order></author></authors><documents><document><filename>71022__35706__6985a2612d384e3382cae4d0841551d4.pdf</filename><originalFilename>Horn2025.pdf</originalFilename><uploaded>2025-11-28T13:41:12.6961182</uploaded><type>Output</type><contentLength>238583</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><documentNotes>Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
| spelling |
2026-02-23T14:49:51.5366031 v2 71022 2025-11-28 Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2025-11-28 MEDS Journal Article The Lancet 406 10522 2927 2944 Elsevier BV 0140-6736 1474-547X 20 12 2025 2025-12-20 10.1016/s0140-6736(25)02165-8 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Not Required This study was funded by Eli Lilly and Company. 2026-02-23T14:49:51.5366031 2025-11-28T13:40:28.3195636 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Deborah B Horn 1 Donna H Ryan 2 Sanja Giljanovic Kis 3 Breno Alves 4 Yiming Mu 5 Sin Gon Kim 6 Jens Aberle 7 Steve Bain 0000-0001-8519-4964 8 Sheryl Allen 9 Elizabeth Sarker 10 Qiwei Wu 11 Adam Stefanski 12 Irina Jouravskaya 13 71022__35706__6985a2612d384e3382cae4d0841551d4.pdf Horn2025.pdf 2025-11-28T13:41:12.6961182 Output 238583 application/pdf Accepted Manuscript true Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention). true eng https://creativecommons.org/licenses/by/4.0/ |
| title |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial |
| spellingShingle |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Steve Bain |
| title_short |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial |
| title_full |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial |
| title_fullStr |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial |
| title_full_unstemmed |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial |
| title_sort |
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial |
| author_id_str_mv |
5399f4c6e6a70f3608a084ddb938511a |
| author_id_fullname_str_mv |
5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain |
| author |
Steve Bain |
| author2 |
Deborah B Horn Donna H Ryan Sanja Giljanovic Kis Breno Alves Yiming Mu Sin Gon Kim Jens Aberle Steve Bain Sheryl Allen Elizabeth Sarker Qiwei Wu Adam Stefanski Irina Jouravskaya |
| format |
Journal article |
| container_title |
The Lancet |
| container_volume |
406 |
| container_issue |
10522 |
| container_start_page |
2927 |
| publishDate |
2025 |
| institution |
Swansea University |
| issn |
0140-6736 1474-547X |
| doi_str_mv |
10.1016/s0140-6736(25)02165-8 |
| publisher |
Elsevier BV |
| college_str |
Faculty of Medicine, Health and Life Sciences |
| hierarchytype |
|
| hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
| hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
| department_str |
Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science |
| document_store_str |
1 |
| active_str |
0 |
| published_date |
2025-12-20T05:28:42Z |
| _version_ |
1858617446719553536 |
| score |
11.098149 |